Thomas Abrams, MD
Medical Oncology · Boston, MANPI 1184693947
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $89,727 of the $118,006 with a category attached, or 76.0%. It is spread thinly across 11 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2021 at $33,968 and has fallen 88.5% since, to $3,898 in 2025.
Across 91 payments — averaging $1296.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$25K
- E.r. Squibb & Sons, L.L.C.$21K
- Eisai Inc.$21K
- Exelixis Inc.$17K
- Ipsen Biopharmaceuticals, Inc$13K
- Merck$6K
- plus $16K from 5 others
Across 30 payments — averaging $11,613 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taiho Oncology, Inc.$156K
- AbbVie$131K
- AVEO Pharmaceuticals, Inc.$52K
- AstraZeneca$10K
What the payments were for
- Consulting fees$89,72776%
- Speaking & faculty fees$18,81016%
- Travel & lodging$7,5806%
- Food & beverage$1,8902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $24,806 |
| E.r. Squibb & Sons, L.L.C. | 4 | $21,295 |
| Eisai Inc. | 20 | $20,657 |
| Exelixis Inc. | 14 | $16,657 |
| Ipsen Biopharmaceuticals, Inc | 15 | $13,186 |
| Merck | 7 | $5,900 |
| Eli Lilly | 1 | $4,888 |
| Agios Pharmaceuticals, Inc. | 6 | $3,942 |
| Histosonics, Inc. | 2 | $2,995 |
| Sirtex Medical Inc | 3 | $2,781 |
| Servier Pharmaceuticals LLC | 1 | $900 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,006 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 24 | $282,136 |
| EliquisApixaban | 13 | $15,854 |
| Ondansetron Hcl | 12 | $851 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 22 | $516 |
| Oxycodone Hcl | 34 | $451 |
| Omeprazole | 20 | $445 |
| Sodium Chloride0.9 % Sodium Chloride | 36 | $322 |
| Methylphenidate Hcl | 15 | $207 |
| Potassium Chloride | 11 | $198 |
| Gabapentin | 13 | $128 |
| Ondansetron OdtOndansetron | 11 | $124 |
| Amlodipine Besylate | 12 | $108 |
| Levothyroxine Sodium | 13 | $66 |
| Lorazepam | 21 | $49 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.